Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
First Lady Jill Biden Leaves Isolation After Testing Negative for COVID-19 Twice
MONDAY, Aug. 22, 2022 (HealthDay News) -- After testing positive for COVID-19...
Heart Disease Targets Black Americans and Poverty, Unemployment Are Big Reasons Why
TUESDAY, Aug. 15, 2023 (HealthDay News) -- What researchers call 'social...
Windy Days Are Safer Days When It Comes to COVID-19
FRIDAY, Dec. 3, 2021 (HealthDay News) -- If you're getting together with others...
Single-Visit Sample Collection Recommended for Hep C Testing
FRIDAY, July 14, 2023 (HealthDay News) -- Use of strategies that require...